LARIMAR THERAPEUTICS

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

11 Mar 2024 13:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

06 Mar 2024 13:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

16 Feb 2024 13:20:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

14 Feb 2024 03:15:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Proposed Underwritten Public Offering

13 Feb 2024 13:18:34 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia

12 Feb 2024 04:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

14 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

01 Nov 2023 13:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

03 Oct 2023 13:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

31 Aug 2023 13:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

10 Aug 2023 04:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

17 Jul 2023 13:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Set to Join Russell 3000® Index

21 Jun 2023 13:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results

15 May 2023 04:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days

28 Mar 2023 13:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results

14 Mar 2023 04:00:01 By Nasdaq GlobeNewswire

Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer

07 Feb 2023 13:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

21 Nov 2022 13:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

10 Nov 2022 04:00:04 By Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day

07 Nov 2022 13:05:01 By Nasdaq GlobeNewswire